NAV

Desomorphine

Identification

Name
Desomorphine
Accession Number
DB01531
Description
Not Available
Type
Small Molecule
Groups
Experimental, Illicit
Structure
Thumb
3D
Similar Structures
Weight
Average: 271.36
Monoisotopic: 271.15722892
Chemical Formula
C17H21NO2
Synonyms
  • 4,5-epoxy-3-hydroxy-n-methylmorphinan
  • 6-deoxy-7,8-dihydromorphine
  • Deoxydihydromorphine D
  • Desomorphine
  • Dihydrodeoxymorphine
  • Dihydrodesoxymorphine D
External IDs
  • IDS-ND-002
  • IDS-ND-002(SECT.3)

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Desomorphine.
AcetophenazineThe risk or severity of hypotension and CNS depression can be increased when Acetophenazine is combined with Desomorphine.
AclidiniumThe risk or severity of adverse effects can be increased when Desomorphine is combined with Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Desomorphine is combined with Agomelatine.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Desomorphine.
AlimemazineThe risk or severity of hypotension and CNS depression can be increased when Alimemazine is combined with Desomorphine.
AlloinThe therapeutic efficacy of Alloin can be decreased when used in combination with Desomorphine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Desomorphine.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Desomorphine.
AlprazolamThe risk or severity of adverse effects can be increased when Desomorphine is combined with Alprazolam.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as morphinans. These are polycyclic compounds with a four-ring skeleton with three condensed six-member rings forming a partially hydrogenated phenanthrene moiety, one of which is aromatic while the two others are alicyclic.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Morphinans
Sub Class
Not Available
Direct Parent
Morphinans
Alternative Parents
Phenanthrenes and derivatives / Tetralins / Coumarans / Aralkylamines / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Piperidines / Trialkylamines / Oxacyclic compounds / Azacyclic compounds
show 2 more
Substituents
1-hydroxy-2-unsubstituted benzenoid / Alkyl aryl ether / Amine / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Coumaran / Ether / Hydrocarbon derivative
show 13 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
7OP86J5E33
CAS number
427-00-9
InChI Key
LNNWVNGFPYWNQE-GMIGKAJZSA-N
InChI
InChI=1S/C17H21NO2/c1-18-8-7-17-11-3-2-4-14(17)20-16-13(19)6-5-10(15(16)17)9-12(11)18/h5-6,11-12,14,19H,2-4,7-9H2,1H3/t11-,12+,14-,17+/m0/s1
IUPAC Name
(1S,5R,13S,17R)-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7,9,11(18)-trien-10-ol
SMILES
[H][C@@]12CCC[C@@]3([H])[C@@]4([H])CC5=CC=C(O)C(O1)=C5[C@@]23CCN4C

References

General References
Not Available
PubChem Compound
5362456
PubChem Substance
46506785
ChemSpider
4515044
ChEBI
135119
ChEMBL
CHEMBL2106274
ZINC
ZINC000004215567
Wikipedia
Desomorphine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.86 mg/mLALOGPS
logP2.5ALOGPS
logP2.11ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)10.35ChemAxon
pKa (Strongest Basic)9.38ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area32.7 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity77.8 m3·mol-1ChemAxon
Polarizability29.99 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9964
Blood Brain Barrier+0.9976
Caco-2 permeable+0.8647
P-glycoprotein substrateSubstrate0.7728
P-glycoprotein inhibitor INon-inhibitor0.8039
P-glycoprotein inhibitor IINon-inhibitor0.9509
Renal organic cation transporterInhibitor0.6957
CYP450 2C9 substrateNon-substrate0.7987
CYP450 2D6 substrateSubstrate0.8615
CYP450 3A4 substrateSubstrate0.7723
CYP450 1A2 substrateNon-inhibitor0.753
CYP450 2C9 inhibitorNon-inhibitor0.9425
CYP450 2D6 inhibitorInhibitor0.5254
CYP450 2C19 inhibitorNon-inhibitor0.7726
CYP450 3A4 inhibitorNon-inhibitor0.7977
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9193
Ames testNon AMES toxic0.6475
CarcinogenicityNon-carcinogens0.9564
BiodegradationNot ready biodegradable0.9841
Rat acute toxicity3.0641 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7496
hERG inhibition (predictor II)Non-inhibitor0.8412
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.57 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on July 31, 2007 13:10 / Updated on February 21, 2021 18:51